Trials / Active Not Recruiting
Active Not RecruitingNCT06405633
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants With AATD Pi*ZZ on WVE-006 (RestorAATion-2)
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Wave Life Sciences Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose (SAD) and Period 2 multiple ascending doses (MAD), respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | WVE-006 | RNA editing oligonucleotide |
Timeline
- Start date
- 2024-07-19
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2024-05-08
- Last updated
- 2026-04-14
Locations
9 sites across 6 countries: Australia, Canada, Finland, Germany, New Zealand, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06405633. Inclusion in this directory is not an endorsement.